SCHEMBL17095515

SCHEMBL17095515

CCC(C)NC(=O)c1n[nH]c2ccc(-c3cccnc3)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 20/20 1.00
WNT1 P04628 12/20 0.66
CLK2 P49760 2/20 0.66
CLK3 P49761 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17095514 1.00 DYRK1A (1.00) DYRK1AWNT1CLK2CLK3
SCHEMBL17095667 1.00 DYRK1A (1.00) DYRK1AWNT1CLK2CLK3
SCHEMBL17095451 0.89 DYRK1A (1.00) DYRK1AWNT1CLK2CLK3
SCHEMBL17096212 0.85 DYRK1A (1.00) DYRK1AWNT1
SCHEMBL17096213 0.85 DYRK1A (1.00) DYRK1AWNT1
SCHEMBL17095854 0.84 DYRK1A (1.00) DYRK1AWNT1CLK2CLK3
SCHEMBL17095669 0.81 DYRK1A (1.00) DYRK1AWNT1CLK2CLK3
SCHEMBL28127575 0.80 DYRK1A (0.80) DYRK1AWNT1CLK2CLK3
SCHEMBL17121391 0.80 DYRK1A (0.78) DYRK1AWNT1CLK2CLK3
SCHEMBL17095971 0.79 DYRK1A (1.00) DYRK1AWNT1CLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669240-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-06-02 US claimed
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-05-10 US claimed
CN-106535890-A 5-substituted indazole-3-carboxamides and preparation and use thereof 萨穆梅德有限公司 2017-03-22 CN claimed
EP-3119393-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF Samumed, LLC (US) 2017-01-25 EP claimed
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2015-09-24 US claimed
WO-2015143380-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF SAMUMED, LLC (US) 2015-09-24 WO claimed
US-10669240-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-06-02 US disclosed
US-10669240-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-06-02 US disclosed
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-05-10 US disclosed
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-05-10 US disclosed
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-05-10 US disclosed
US-9745271-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2017-08-29 US disclosed
US-9745271-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2017-08-29 US disclosed
US-9745271-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2017-08-29 US disclosed
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2015-09-24 US disclosed
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2015-09-24 US disclosed
WO-2015143380-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF SAMUMED, LLC (US) 2015-09-24 WO disclosed
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, WNT1 DYRK1A 1/4885WNT1 3/4885CLK2 86/4885
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, WNT1 DYRK1A 1/4885WNT1 3/4885CLK2 86/4885
US-10669240-B2 5-substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, WNT1 DYRK1A 1/4885WNT1 3/4885CLK2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.